NEW YORK, May 7, 2019 /PRNewswire/ -- Renalytix AI plc (LON: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today a collaboration with University Medical Center Groningen (UMCG), Netherlands, to evaluate KidneyIntelX™ across over 3,500
Download full announcement Provides priority regulatory review of AI-enabled diagnostic for fast-progressing kidney disease Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces that it has been granted Breakthrough Device
Provides Priority Regulatory Review of AI-Enabled Diagnostic for Fast-Progressing Kidney Disease NEW YORK, May 2, 2019 /PRNewswire/ -- Renalytix AI plc (LON: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today that it has been granted
Download full announcement The Company was informed that today, Christopher Mills, a non-executive director, completed the purchase of 3,168 ordinary shares of 0.25 pence each (“Ordinary Shares”) in the Company at a price of 112 pence per share. Following this purchase, Mr Mills is interested in
Download full announcement EKF Diagnostics Holdings (AIM: EKF), the AIM quoted point-of-care business, notes the announcement by Renalytix AI plc (AIM: RENX) (“RenalytixAI”), that on 26 April 2019 EKF Diagnostics plc (“EKF”) acquired 100,074 ordinary RenalytixAI shares of £0.0025 each.
Download full announcement NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii : Renalytix AI Plc 1b.
Download full announcement RenalytixAI machine learning approach outperformed current standard of care in 1,369 patient study Renalytix AI plc(AIM: RENX), the developer of artificial intelligence-enabled diagnostics for kidney disease, announces publication of results generated by a confirmation
Download full announcement Renalytix AI plc (AIM: RENX), the AIM quoted developer of artificial intelligence-enabled diagnostics for kidney disease, announces its inaugural unaudited interim results for the six months ended 31 December 2018. Operational highlights Secured agreements for
Download full announcement Investigators include leading transplant clinicians from Emory University, the University of Manitoba, the Westmead Hospital Sydney, and Icahn School of Medicine at Mount Sinai. Renalytix AI plc(LON: RENX), a developer of artificial intelligence-enabled clinical
Investigators include leading transplant clinicians from Emory University, the University of Manitoba, the Westmead Hospital Sydney, and Icahn School of Medicine at Mount Sinai NEW YORK, March 22, 2019 /PRNewswire/ -- Renalytix AI plc (LON: RENX), a developer of artificial intelligence-enabled
